MDxHealth (MDXH) Registration Filing summary

Company overview and business model

• Commercial-stage precision diagnostics company focused on non-invasive, cost-effective urologic solutions, primarily for prostate cancer diagnosis and management.

• Core testing solutions include ExoDx, Confirm mdx, and Genomic Prostate Score (GPS), with additional tests for related urologic conditions.

• Over 7,000 physicians have ordered more than 500,000 tests; products are included in major U.S. clinical guidelines and have Medicare reimbursement.

• Recent acquisition of Exosome Diagnostics, Inc. (ExoDx test) for up to $15 million, with a mix of stock and deferred payments.

• Solely listed on Nasdaq since December 2023 after delisting from Euronext Brussels.

Financial performance and metrics

• As of December 31, 2024, accumulated deficit was $369.5 million; net loss for 2024 was $38.1 million; net cash outflows from operations were $18.5 million.

• Confirm mdx and GPS tests accounted for 80% of 2024 revenue; Medicare represented 41% of 2024 revenues.

• Outstanding deferred acquisition payments: up to $10 million for Exosome Diagnostics and up to $54.5 million for GPS business.

• $100 million senior secured credit facility with OrbiMed, with $80 million drawn as of March 2025 and $20 million available subject to conditions.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for general corporate and working capital purposes, including product development and commercialization expansion.

• Management retains broad discretion over allocation of proceeds; plans may be updated in future prospectus supplements.